|
Two Rho kinases (ROCK), ROCK-I and ROCK-II, act downstream of the G protein Rho to regulate cytoskeletal stability. The Rho kinases play important roles in diverse cellular functions including cell adhesion and proliferation, smooth muscle contraction, and stem cell renewal.123 Glycyl-H-1152 is a selective and potent ROCK inhibitor (IC50 = 11.8 nM for ROCK-II).4 It is a glycylated isoquinoline compound derived from the therapeutically-important ROCK inhibitor HA-1077 (Fasudil hydrochloride) and exhibits better specificity. Thus, it poorly inhibits calcium/calmodulin kinase II, protein kinase G, and Aurora A (IC50 = 2.57, 2.35, and 3.26 μM, respectively) as well as PKA or PKC (IC50 >10 μM for each).4 The potency of Glycyl-H-1152 is superior to that of other ROCK inhibitors, including Y-27632 (Ki = 220 nM) and HA-1077 (IC50 = 158 nM).4,5
|
|
1
Olson, M.F. Applications for ROCK kinase inhibition. Curr Opin Cell Biol 20 242-248 (2008).
2
Narumiya, S., Tanji, M., Ishizaki, T. Rho signaling, ROCK and mDia1, in transformation, metastasis and invasion. Cancer Metastasis Rev 28 65-76 (2009).
3
Watanabe, K., Ueno, M., Kamiya, D., et al. A ROCK inhibitor permits survival of dissociated human embryonic stem cells. Nature Biotechnology 25(6) 681-686 (2007).
4
Tamura, M., Nakao, H., Yoshizaki, H., et al. Development of specific Rho-kinase inhibitors and their clinical application. Biochim Biophys Acta 1754 245-252 (2005).
5
Ishizaki, T., Uehata, M., Tamechika, I., et al. Pharmacological properties of Y-27632, a specific inhibitor of Rho-associated kinases. Mol Pharmacol 57 976-983 (2000).
|